Parietal Cell Dysfunction: A Rare Cause of Gastric Neuroendocrine Neoplasm with Achlorhydria and Extreme Hypergastrinemia

Yasuaki Abe¹, Waku Hatta¹, Sho Asonuma², Tomoyuki Koike¹, Hiroko Abe¹, Yohei Ogata¹, Masahiro Saito¹, Xiaoyi Jin¹, Takeshi Kanno¹, Kaname Uno¹, Naoki Asano¹, Akira Imatani¹, Fumiyoshi Fujishima³, Hironobu Sasano³ and Atsushi Masamune¹

Abstract: A 69-year-old woman with multiple neuroendocrine neoplasms (NENs) was referred to our hospital. Although she had extreme hypergastrinemia (11,675 pg/mL), no findings that indicated types I to III gastric NENs were found. Although gastric corpus atrophy was suspected on conventional white-light imaging, findings on magnifying endoscopy with narrow-band imaging indicated no severe atrophy. A biopsy from the background fundic gland mucosa revealed no atrophic changes, parietal cells with vacuolated cytoplasm and negative findings for H⁺K⁺-ATPase. Thus, this case was diagnosed as multiple NENs with parietal cell dysfunction. Neither progression nor metastasis has been confirmed during two-year follow-up.

Key words: neuroendocrine neoplasms, parietal cell dysfunction, achlorhydria, hypergastrinemia

(Intern Med 61: 2441-2448, 2022) (DOI: 10.2169/internalmedicine.8253-21)

Introduction

Gastric neuroendocrine neoplasms (NENs) are classified into three subgroups according to the presence of hypergastrinemia or underlying diseases (1, 2). This classification is useful for determining the treatment strategy for gastric NENs, as these subgroups correlate with metastasis and the prognosis. NENs that do not match the above classification have rarely been reported, and such cases show parietal cell dysfunction in the background mucosa of the stomach.

We herein report a rare case of multiple gastric NENs with parietal cell dysfunction and extreme hypergastrinemia.

Case Report

A 69-year-old Japanese woman with no complaints underwent esophagogastroduodenoscopy (EGD) at a nearby hospital and was found to have multiple elevated gastric lesions diagnosed as NENs by a biopsy. Since it was difficult to diagnose the type of gastric NENs, she was referred to our hospital. She had no history of proton pump inhibitor usage, no history of Helicobacter pylori eradication, and no family history of multiple neuroendocrine neoplasia-1 (MEN-1) or other gastric disorders.

Conventional white-light imaging (C-WLI) at our hospital showed 6 yellowish submucosal tumor-like lesions with vasodilation, all of which were <5 mm in maximal diameter, in the fundic gland area of the stomach (Fig. 1A, B). Magnifying endoscopy with narrow-band imaging (ME-NBI) showed an absent microsurface pattern and vasodilation on the top of the tumor (Fig. 1C). The biopsy specimens revealed that the tumor was covered with a monolayer of foveolar epithelium (Fig. 2A), and small nests and cords of polygonal neoplastic cells were present within a fibrotic stroma (Fig. 2B, C). The tumor cells were positive for chromogranin A (Fig. 2D), synaptophysin (Fig. 2E) and CD56 (Fig. 2F). Although atrophic changes in the gastric corpus...
Figure 1. Endoscopic images of gastric NENs. C-WLI showed multiple gastric NENs (light-blue arrows) (A). A NEN located on the greater curvature of the upper body appeared to be a submucosal tumor-like lesion with vasodilation (B). ME-NBI revealed vasodilation and the absence of a microsurface pattern on the top of the tumor (C). NEN: neuroendocrine neoplasm, C-WLI: conventional white-light imaging, ME-NBI: magnifying endoscopy with narrow-band imaging

Figure 2. Histopathological findings of a gastric NEN in a biopsy specimen. Hematoxylin and Eosin staining revealed that the tumor was covered with a monolayer of foveolar epithelium (A, blue arrow), and nests and cords of small uniform cuboidal cells were present within a fibrotic stroma (B, C). Immunostaining revealed that the tumor cells were positive for chromogranin A (D), synaptophysin (E) and CD56 (F). Bar=100 μm. NEN: neuroendocrine neoplasm
Figure 3. Endoscopic images of background gastric mucosa. Discolored mucosa with marked vascular visibility on the entire area of the greater curvature of the corpus along with the disappearance of folds without an atrophic border indicated severe atrophic changes in the corpus in C-WLI (A). ME-NBI in the corpus revealed a slightly enlarged, round pit with unclear or irregular subepithelial capillary networks in the corpus (B), indicating the absence of severe gastric atrophy. In the antrum, the visibility of the vascular pattern was negative on C-WLI (C), and subepithelial capillary networks and surrounding circular pits were observed on ME-NBI (D), indicating no atrophy in the gastric antrum. C-WLI: conventional white-light imaging, ME-NBI: magnifying endoscopy with narrow-band imaging.

were suspected on C-WLI, which showed discolored mucosa with vascular visibility on the entire area of the greater curvature of the corpus (Fig. 3A), ME-NBI revealed slightly enlarged, round pits with unclear or irregular subepithelial capillary networks in the corpus (Fig. 3B), suggesting that there may have been no severe gastric atrophy (3, 4). In the antrum, the visibility of the vascular pattern was negative on C-WLI (Fig. 3C), and subepithelial capillary networks and surrounding circular pits were observed on ME-NBI (Fig. 3D), which indicated that there was no atrophy in the gastric antrum (4). No endoscopic findings suggestive of certain diseases, such as enterochromaffin-like (ECL) cell hyperplasia/dysplasia, were observed in the background gastric mucosa.

In the laboratory examination (Table 1), marked hypergastrinemia (11,675 pg/mL) was present; however, no abnormal findings were observed in the titers of serum IgG antibodies against H. pylori (H. pylori-LATEX “SEIKEN”, Denka Ltx, Tokyo, Japan), autoantibodies against intrinsic factor or parietal cell, serum albumin, calcium or intact parathyroid hormone values. H. pylori was negative, as also confirmed by the urea breath test (1.6‰). There were no findings suggestive of gastrinoma on computed tomography (CT), somatostatin receptor scintigraphy, selective arterial calcium injection test (Fig. 4) or abdominal angiography. The mean intragastric pH on the 24-hour pH monitoring test was 6.67, indicating a non-acidic condition. We also conducted an endoscopic gastrin test, which estimates the gastrin-stimulated gastric acid secretory response and correlates well with the peak acid output and maximal acid output (5). Although hypochlorhydria and profound hypochlorhydria are defined based on endoscopic gastrin test results of <2.1 and <0.6 mEq/10 min, respectively (6, 7), the value in this case was 0 mEq/10 min, indicating achlorhydria.

An endoscopic biopsy from the endoscopically non-NEN fundic gland mucosa revealed no atrophic changes in the
The selective arterial calcium injection test. This test showed no significant increase in the serum gastrin level in any of the evaluated arteries.

![Image](image-url)

**Figure 4.** The selective arterial calcium injection test. This test showed no significant increase in the serum gastrin level in any of the evaluated arteries.

Table 1. Results of Blood Examination.

| Measured value | Normal range | Measured value | Normal range |
|----------------|--------------|----------------|--------------|
| WBC            | 5.2 $10^3/\mu L$ | 3.3-8.6 | Ferritin | 17.5 ng/mL | 12-60 |
| RBC            | 379 $10^3/\mu L$ | 386-492 | Intact PTH | 61 pg/mL | 10-65 |
| Hb             | 11.7 g/dL | 11.6-14.8 | PG I | 22.7 ng/mL | >70 |
| Ht             | 34.7 % | 35.1-44.4 | PG II | 12.2 ng/mL | |
| PLT            | 28.1 $10^3/\mu L$ | 15.8-34.8 | PG I/II | 1.9 | >3 |
| TP             | 7.6 g/dL | 6.6-8.1 | Vitamin B12 | 744 pg/mL | 180-914 |
| Albumin        | 4.3 g/dL | 4.1-5.1 | Folic acid | 14.9 ng/mL | ≥4.0 |
| Na             | 139 mmol/L | 138-145 | Gastrin | 11,675 pg/mL | 42-200 |
| K              | 4.6 mmol/L | 3.6-4.8 | H. pylori antibody | <3 U/mL | <3 |
| Cl             | 102 mmol/L | 101-108 | Parietal cell antibody | <10 | <10 |
| Ca             | 9.7 mg/dL | 8.8-10.1 | Intrinsic factor antibody | (-) | (-) |

WBC: white blood cell, RBC: red blood cell, Hb: hemoglobin, Ht: hematocrit, PLT: platelet, TP: total protein, Na: sodium, K: potassium, Cl: chlorine, Ca: calcium, PTH: parathyroid hormone, PG: pepsinogen, H. pylori antibody: IgG antibody against *Helicobacter pylori*

---

**Discussion**

Gastric NENs account for 5.6-8.7% of all digestive NENs (10-12), and most cases with gastric NENs are subdivided into three types: type I, gastric NENs that develop against a background of atrophic gastritis (autoimmune gastritis or *H. pylori*-related chronic gastritis) and achlorhydria with hypergastrinemia; type II, gastric NENs that occur in the setting of gastrinoma and hyperchlorhydria that occurs as a part of MEN-1; and type III, gastric NENs that occur sporadically without hypergastrinemia (1, 2). To date, only five cases of gastric NENs associated with parietal cell dysfunction have been reported worldwide (Table 2) (9, 13-15). Vacuolation of parietal cells is a characteristic of parietal cell dysfunction, but it is reported to be associated with long-term proton pump inhibitor use or *H. pylori* infection (16). In the present case, the patient had no history of long-term proton pump inhibitor use, and *H. pylori* findings were negative, with no history of its eradication. Furthermore, parietal cell protrusion and dilated fundic glands with completely negative staining for H’K’-ATPase were also observed. We therefore diagnosed this case as a gastric NEN with parietal cell dysfunction, making it the sixth case of such a tumor.
Figure 5. Histopathological findings of parietal cell dysfunction. Hematoxylin and Eosin staining showed dilated glands and no atrophic change of the fundic glands (A). The parietal cell cytoplasm was vacuolated (B). On immunostaining, the chief cells were positive for pepsinogen (C), but the parietal cells were completely negative for H⁺K⁺-ATPase (D). In the deeper mucosa, mononuclear cell aggregates were apparent (E). Immunostaining revealed that the number of mononuclear cells positive for CD8 (F) was small, indicating very mild inflammation. Bar=100 μm.

Figure 6. Histopathological findings of ECL cell hyperplasia/dysplasia. Small nodules of ECL cells <500 μm in diameter were found around the muscularis mucosa on Hematoxylin and Eosin staining (A) and synaptophysin staining (B), which was diagnosed as ECL cell hyperplasia/dysplasia. In the subclassification of ECL cell hyperplasia/dysplasia, these nodules were diagnosed as micronodular hyperplasia because the size of each nodule was <150 μm. Parietal cell protrusion was also found (A, blue arrow). ECL: enterochromaffin-like

Figure 7. Histopathological findings of antral mucosa. An endoscopic biopsy of the endoscopically non-NEN antral mucosa showed no intestinal metaplasia and the presence of pyloric glands (A, B). NEN: neuroendocrine neoplasm
This type of NEN cannot be subdivided into the traditional three types of NENs because these tumors showed hypergastrinemia and achlorhydria with neither chronic atrophic gastritis nor MEN-1 in the underlying disease. However, NENs with parietal cell dysfunction are a type of ECL-cell NEN, and the mechanism underlying the incidence of such NENs is similar to that of type I gastric NENs. In either type of NEN, dysfunction or depletion of parietal cells causes achlorhydria, hypergastrinemia due to G cell hyperplasia, ECL cell hyperplasia and finally NENs (9). Although the prognosis of NENs with parietal cell dysfunction is unclear, the mechanism of incidence might indicate a relatively good prognosis, similar to that of type I gastric NEN.

The diagnostic criteria for autoimmune gastritis have not been established, but the presence of parietal cell antibody and intrinsic factor antibody-negative cases has been reported (17). In the present case, NENs due to autoantibody-negative autoimmune gastritis and parietal cell dysfunction were considered as differential diagnoses. Although parietal cell dysfunction showed no atrophic change in the background gastric mucosa in the previous cases (9, 15), severe atrophic changes in the corpus were suspected in C-WLI because the endoscopic findings met the criteria for severe atrophic gastritis (18). In contrast, ME-NBI revealed a slightly enlarged, round pit with unclear or irregular subepithelial capillary networks, which indicates only mild gastritis according to the classification proposed by Tahara et al. (3). Among cases with this ME-NBI finding, 85.7% were reported to lack severe gastric atrophy by histopathology (19).

Indicating very mild inflammation in the histopathology. The reason for the discrepancy in gastric atrophy between C-WLI and ME-NBI or histopathology. The reason for the discrepancy in gastric atrophy between C-WLI and ME-NBI or histopathological findings is unclear; however, vacuolated parietal cell cytoplasm might be associated with a thin, discolored mucosa with marked vascular visibility on C-WLI. In this regard, the ME-NBI findings might help differentiate parietal cell dysfunction from autoantibody-negative autoimmune gastritis other than the early type, as described below.

ME-NBI showed an absent microsurface pattern on the top of the gastric NEN, which reflects the fact that this tumor grew beneath the epithelium without a gland structure. This ME-NBI finding is in accordance with the characteristics described in a previous report about gastric NEN (20).

Regarding the histopathology of the biopsy specimen, the tumor was located beneath a monolayer of foveolar epithelium. Tumors without a gland structure, such as lymphoma and poorly differentiated cancer covered with a thin normal gastric layer, often have an absent microsurface pattern on ME-NBI, and this was also true in the present case.

This case showed an extremely high serum gastrin level (11,675 pg/mL). Previous studies defined values exceeding 300-450 pg/mL as indicating the presence of hypergastrinemia.

---

**Table 2. Reports of Gastric NENs with Parietal Cell Dysfunction.**

| References | Age (y)/sex | Diameter and number of tumors | Endoscopic findings of background gastric mucosa in C-WLI | Serum gastrin level (pg/mL) | Autoantibody | Hematoxylin and Eosin staining for parietal cells | Immunostaining of H⁺K⁺-ATPase | Treatment, clinical outcome |
|------------|-------------|-------------------------------|------------------------------------------------------|-----------------------------|-------------|--------------------------------------------------|-----------------------------|-----------------------------|
| 9          | 37/male     | <5 mm, >20                    | No atrophy                                           | 6,800                       | PCA, normal; IFA, negative | Parietal cell protrusion, vacuolation, dilated fundic glands | Completely negative for α and β subunits | Observation                 |
| 9          | 36/male     | Small, multiple               | No atrophy                                           | 2,600                       | PCA, normal; IFA, negative | Parietal cell protrusion, vacuolation, dilated fundic glands | Completely negative for α and β subunits | Antrectomy                  |
| 13         | 47/male     | 6-15 mm, 19                   | No atrophy                                           | >800                        | PCA, normal; IFA, negative | Dilated fundic glands, hypertrophy and hyperplasia of parietal cells | NA                           | Proximal gastrectomy, with lymphadenectomy, no metastasis |
| 14         | 54/male     | 1-13 mm, >10                  | Thickened gastric folds                               | 1,400                       | PCA, normal                | Dilated oxyntic glands, hypertrophy and hyperplasia of parietal cells | Weak stain for β subunit     | Subtotal gastrectomy with antrectomy, Positive for LN metastasis |
| 15         | 50/female   | 2-12 mm, multiple             | No atrophy                                           | 1,400                       | PCA, normal                | Vakuolation, dilated oxyntic glands, hypertrophy and hyperplasia of parietal cells | NA                           | Total gastrectomy with lymphadenectomy, no metastasis |
| Present case | 69/female   | <5 mm, 6                      | Discolored mucosa with marked vascular visibility in the corpus | 11,675                      | PCA, normal; IFA, negative | Parietal cell protrusion, vacuolation, dilated fundic glands | Completely negative          | Observation                 |

NENs: neuroendocrine neoplasms, C-WLI: conventional white light imaging, PCA: parietal cell antibody, IFA: intrinsic factor antibody, NA: no assessment, LN: lymph node.

---

**Reports of Gastric NENs with Parietal Cell Dysfunction.**

**Table 2.** Reports of Gastric NENs with Parietal Cell Dysfunction.
Parietal cell dysfunction and early-stage autoimmune gastritis have been reported, and immune gastritis cannot be ruled out. Recently, several cases evaluate the parietal cell function. First, although we confirmed a lack of H⁺K⁺-ATPase expression on immunostaining, other functions, such as the intrinsic factor production, were also found in these cases (24-26). Although some clinicians believe such high levels of serum gastrin occur frequently in patients with Zollinger-Ellison syndrome (ZES), including MEN-1 (23), this was not the case. Indeed, serum gastrin levels >10,000 pg/mL are also uncommon in patients with ZES, occurring in 4.9-9% of such patients (23). Thus, although the presence/absence of hypergastrinemia is useful for distinguishing type III from type I, type II, or parietal cell dysfunction, it may be difficult to distinguish the latter three types of gastric NENs by the serum gastrin level alone. This case has some limitations in its applicability to the diagnosis of parietal cell dysfunction. First, although we confirmed a lack of H⁺K⁺-ATPase expression on immunostaining, other functions, such as the intrinsic factor production, were unknown. However, to our knowledge, there are no other immunostaining approaches that can evaluate the parietal cell function. Second, early-stage autoimmune gastritis cannot be ruled out. Considering the similar histopathological findings between parietal cell dysfunction and early-stage autoimmune gastritis (Table 3), we hypothesize that parietal cell dysfunction and autoantibody-negative early-stage autoimmune gastritis are similar diseases. However, to confirm this hypothesis, long-term observation to evaluate whether or not the corporal gastritis is progressing is required.

In conclusion, we experienced a rare case of multiple NENs with parietal cell dysfunction that had extreme hypergastrinemia. When we encounter patients with multiple gastric NENs with achlorhydria and hypergastrinemia, parietal cell dysfunction should be considered as a differential diagnosis. ME-NBI may help lead to the diagnosis of such a disease, and a subsequent histopathological evaluation of the fundic gland mucosa is required.

The authors state that they have no Conflict of Interest (COI).

Table 3. Comparison of Characteristics between Parietal Cell Dysfunction and Early-stage Autoimmune Gastritis.

|                          | Parietal cell dysfunction | Early-stage autoimmune gastritis |
|--------------------------|---------------------------|----------------------------------|
| Endoscopic finding in corpus | • No atrophy              | • Polygonal areae gastricae surrounded by a reticular border in a mosaic-like pattern |
|                          | • Thickened gastric folds | • Edematous mucosa and slight swelling of the areae gastricae |
|                          | • Discolored mucosa with marked vascular visibility | • Discolored mucosa and vascular visibility |
| Hematoxylin and Eosin staining in corpus | • Parietal cell protrusion | • Parietal cell protrusion |
|                          | • Parietal cell vacuolation | • Parietal cell vacuolation |
|                          | • Dilated fundic glands | • Dilated fundic glands |
|                          | • Inflammation in deep mucosa | • Inflammation in deep mucosa |
|                          | • Reduction of parietal cells | |
| Immunostaining for H⁺K⁺-ATPase | • Negative (or weak) | • Negative or weak in some areas |
| Immunostaining for pepsinogen | • Positive | • Negative or weak in some areas |
| Autoantibody | • PCA, normal | • PCA, high (possibly normal in some cases) |
|             | • IFA, negative | • IFA, positive or negative |

PCA: parietal cell antibody, IFA: intrinsic factor antibody

mia in gastric NENs (21, 22). Among gastric NENs with hypergastrinemia, the serum gastrin levels in cases with parietal cell dysfunction were reported to be 1,400-6,800 pg/mL, and those in some patients with type I NENs were >10,000 pg/mL (21). Although some clinicians believe such high levels of serum gastrin occur frequently in patients with Zollinger-Ellison syndrome (ZES), including MEN-1 (23), this was not the case. Indeed, serum gastrin levels >10,000 pg/mL are also uncommon in patients with ZES, occurring in 4.9-9% of such patients (23). Thus, although the presence/absence of hypergastrinemia is useful for distinguishing type III from type I, type II, or parietal cell dysfunction in gastric NENs, it may be difficult to distinguish the latter three types of gastric NENs by the serum gastrin level alone.

This case has some limitations in its applicability to the diagnosis of parietal cell dysfunction. First, although we confirmed a lack of H⁺K⁺-ATPase expression on immunostaining, other functions, such as the intrinsic factor production, were unknown. However, to our knowledge, there are no other immunostaining approaches that can evaluate the parietal cell function. Second, early-stage autoimmune gastritis cannot be ruled out. Recently, several cases of early-stage autoimmune gastritis have been reported, and several histopathological findings, such as parietal cell protrusion, dilated fundic glands and a lack of H⁺K⁺-ATPase expression, were also found in these cases (24-26). Although the parietal cell autoantibody titer was normal in the present case, differing from the previous cases (24-26), autoantibody-negative early-stage autoimmune gastritis could not be ruled out. Considering the similar histopathological findings between parietal cell dysfunction and early-stage autoimmune gastritis (Table 3), we hypothesize that parietal cell dysfunction and autoantibody-negative early-stage autoimmune gastritis are similar diseases. However, to confirm this hypothesis, long-term observation to evaluate whether or not the corporal gastritis is progressing is required.

In conclusion, we experienced a rare case of multiple NENs with parietal cell dysfunction that had extreme hypergastrinemia. When we encounter patients with multiple gastric NENs with achlorhydria and hypergastrinemia, parietal cell dysfunction should be considered as a differential diagnosis. ME-NBI may help lead to the diagnosis of such a disease, and a subsequent histopathological evaluation of the fundic gland mucosa is required.

The authors state that they have no Conflict of Interest (COI).

References

1. Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 104: 994-1006, 1993.
2. Delle Fave G, O’Toole D, Sundin A, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology 103: 119-124, 2016.
3. Tahara T, Shibata T, Nakamura M, et al. Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis. Gastrointest Endosc 70: 246-253, 2009.
4. Bansal A, Ulusarac O, Mathur S, et al. Correlation between narrow band imaging and nonneoplastic gastric pathology: a pilot feasibility trial. Gastrointest Endosc 67: 210-216, 2008.
5. Iijima K, Ohara S, Sekine H, et al. A new endoscopic method of gastric acid secretory testing. Am J Gastroenterol 93: 2113-2118, 1998.
6. Hatta W, Iijima K, Koike T, et al. Endoscopic findings for predicting gastric acid secretion status. Dig Endosc 27: 582-589, 2015.
7. Kikuchi H, Fukuda S, Koike T, et al. Association of residual gastric acid secretion with persistent symptoms in gastrosophageal reflux disease patients receiving standard-dose proton pump inhibitor therapy. Esophagus 18: 380-387, 2021.
8. Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classifi-
cation of nonantral gastric endocrine growths in man. Digestion 41: 185-200, 1988.
9. Ishioka M, Hirasawa T, Kavachi H, et al. Enterochromaffin-like cell neuroendocrine tumor associated with parietal cell dysfunction. Gastrointest Endosc 90: 841-845 e1, 2019.
10. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 99: 23-32, 2004.
11. Niederle MB, Hackl M, Kaserer K, et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 17: 909-918, 2010.
12. O’Connor JM, Marmissolle F, Bestani C, et al. Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: results from the large database of a multidisciplinary group clinical multicenter study. Mol Clin Oncol 2: 673-684, 2014.
13. Ooi A, Ota M, Katsuda S, et al. An unusual case of multiple gastric carcinoids associated with diffuse endocrine cell hyperplasia and parietal cell hypertrophy. Endocr Pathol 6: 229-237, 1995.
14. Abraham SC, Carney JA, Ooi A, et al. Achlorhydria, parietal cell hyperplasia, and multiple gastric carcinoids: a new disorder. Am J Surg Pathol 29: 969-975, 2005.
15. Nakata K, Aishima S, Ichimiyahita Y, et al. Unusual multiple gastric carcinoids with hypergastrinemia: report of a case. Surg Today 40: 267-271, 2010.
16. Rahman MA, Karam SM. Gastric parietal cell vacuolation mimicking gastric carcinoma. Histopathology 63: 735-737, 2013.
17. Lahner E, Norman GL, Severi C, et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol 104: 2071-2079, 2009.
18. Kimura K. Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach. Gastroenterology 63: 584-592, 1972.
19. Tahara T, Shibata T, Nakamura M, et al. Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis. Gastrointest Endosc 70: 246-253, 2009.
20. Sato Y. Endoscopic diagnosis and management of type I neuroendocrine tumors. World J Gastrointest Endosc 7: 346-353, 2015.
21. Sato Y, Imamura H, Kaizaki Y, et al. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan. Dig Endosc 26: 377-384, 2014.
22. Vanoli A, La Rosa S, Miceli E, et al. Prognostic evaluations tailored to specific gastric neuroendocrine neoplasms: analysis of 200 cases with extended follow-up. Neuroendocrinology 107: 114-126, 2018.
23. Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 85: 295-330, 2006.
24. Kotera T, Oe K, Kushima R, et al. Multiple pseudopolyps presenting as reddish nodules are a characteristic endoscopic finding in patients with early-stage autoimmune gastritis. Intern Med 59: 2995-3000, 2020.
25. Ayaki M, Aoki R, Matsunaga T, et al. Endoscopic and upper gastrointestinal barium X-ray radiography images of early-stage autoimmune gastritis: a report of two cases. Intern Med 60: 1691-1696, 2021.
26. Kishino M, Yao K, Hashimoto H, et al. A case of early autoimmune gastritis with characteristic endoscopic findings. Clin J Gastroenterol 14: 718-724, 2021.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).